Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Thyroid Cancer and Sunitinib (THYSU)

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Bordeaux Identifier:
First received: August 1, 2007
Last updated: February 27, 2013
Last verified: February 2013

Due to arguments showing that angiogenesis could be involved in progression of metastatic thyroid carcinoma and to objective response during previous studies with sunitinib (an angiogenic oncology drug also known as Sutent), this study, THYSU, is justified to evaluate the efficacy of sunitinib in metastatic thyroid carcinoma. Furthermore, the standard treatment of metastatic thyroid carcinoma when a general treatment is to be prescribed is limited to radioiodine. When radioiodine becomes ineffective, there is no standard treatment despite some use of chemotherapy.

The objective of the trial is to determine the objective tumor response rate (efficacy) in patients with locally advanced or metastatic anaplastic, differentiated or medullary thyroid carcinoma treated with sunitinib; a secondary objective is to evaluate the safety of sunitinib in these patients.

The THYSU trial is a phase II, French multi-center study. This trial's plan is to enroll 75 patients with locally advanced or metastatic anaplastic, differentiated or medullar thyroid carcinoma.

Condition Intervention Phase
Thyroid Carcinoma
Drug: Sunitinib
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 2 of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer

Resource links provided by NLM:

Further study details as provided by University Hospital, Bordeaux:

Primary Outcome Measures:
  • Objective response rate (ORR) : defined as the proportion of patients with confirmed complete (CR) or partial response (PR) according to the RECIST, relative to the total patients enrolled who received at least 1 dose of trial medication [ Time Frame: Every two cycles ]

Secondary Outcome Measures:
  • Evaluate the safety of sunitinib in patients with thyroid carcinoma [ Time Frame: After each cycle of treatment ]
  • Determine time-to-event variables of overall survival, time to: disease progression, response, and duration of response [ Time Frame: variable ]

Enrollment: 71
Study Start Date: August 2007
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sunitinib
Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.
Drug: Sunitinib
Capsule, 12.5 or 50 mg, starting dose level 50 mg daily

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed informed consent.
  • Age ≥ 18.
  • Patients must have a life expectancy of at least 3 months
  • Patients must have a Karnofsky performance status ≥ 70%
  • Patients must have histologically confirmed thyroid cancer (TC)
  • Tumor disease must be progressive (evidence of disease progression within 6 months before starting the study for follicular and medullary thyroid cancer or symptomatic disease)
  • Patients should not be candidates for surgical resection, external beam radiotherapy or radioiodine
  • Patients must have measurable disease defined by Response Evaluation Criteria in Solid Tumors (RECIST), such as at least one lesion at least 2 cm in length by conventional computed tomography (CT) techniques or at least 1 cm by spiral CT scan
  • Patients must not have more than one previous systemic treatment for cancer
  • Resolution of all acute toxic effects of any prior local treatment to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 3.0) grade < 1
  • Patients must have discontinued from radiation therapy at least 4 weeks before start of study treatment and must have recovered from any toxic effects of treatment
  • Blood pressure < 140 / 90 mmHg
  • Patients must have adequate organ function defined as: Platelets > 100 x 10*9/L, Hemoglobin > 8 g/dl, ANC > 1.5 x 10*9/L, Bilirubin < 3 mg/dL, AST and ALT < 2.5 x the upper limit of normal (ULN) or < 5 x the ULN for liver metastases, INR < 1.7 or prothrombin time < 6 sec over ULN, Serum creatinine < 1.5 x ULN
  • Patients with reproductive potential must use medically acceptable contraceptive methods (oral contraception or an intrauterine device [IUD])
  • Willingness and ability to comply with all study procedures
  • Affiliated or profit patient of a social security system

Exclusion Criteria:

  • Prior treatment on sunitinib or other anti-angiogenic therapy
  • NCI CTCAE grade 3 hemorrhage < 4 weeks of starting study treatment
  • Diagnosis of any second malignancy < 3 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months
  • History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease
  • Any of the following within the 12 months prior to study drug administration: severe/unstable angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, including transient ischemic attack, or pulmonary embolism
  • Ongoing cardiac dysrhythmias of NCI CTCAE grade > 2, atrial fibrillation of any grade, or prolongation of the QTc interval to > 450 msec for males or > 470 msec for females
  • Left ventricular ejection fraction ( LVEF) < 50%
  • Hypertension that cannot be controlled by medications
  • Treatment with anticoagulant agents and treatment with therapeutic doses of warfarin currently or within 2 weeks prior to first day of sunitinib administration
  • Inability to swallow oral medications, or presence of active inflammatory bowel disease, partial or complete bowel obstruction or chronic diarrhea
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
  • Pregnancy or breastfeeding
  • Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
  • Receipt of any investigational agent prior to study entry
  • Current treatment on another therapeutic clinical trial
  • Patient under safeguard of justice
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00510640

Centre Paul Papin - 2 rue Moll
Angers, France, 49100
Département Endocrinolo-Diabéto-Nutrition - CHU d'Angers - 4 rue de Larray
Angers, France, 49933
Service d'Oncologie Médicale et de Radiothérapie - Hôpital Saint André - 1 rue Jean Burguet
Bordeaux, France, 33075
Fédération Endocrinologie - Groupe Hospitalier Est - Hôpital neurologique - CHU Lyon - 59 Boulevard Pinel
Bron, France, 69677
Service d'Endocrinologie et maladies métaboliques, Clinique Marc Linquette - rue du Pr Laguesse
Lille, France, 59037
Centre Léon Bérard - Département de Médecine - 28 rue Laennec
Lyon, France, 69373
Service d'Endocrinologie, CHU Timone, AP-HM - 254 rue St Pierre
Marseille, France, 13385
Service des Maladies Endocriniennes - Hôpital Lapeyronie - 191 avenue du Doyen Gaston Giraud
Montpellier, France, 34295
Centre Paul Lamarque - Va d'Aurelle - CRLC Val d'Aurelle - 208 rue des Apothicaires
Montpellier, France, 34298
Centre Antoine Lacassagne - 33 avenue de Valombrose
Nice, France, 06189
Service d'Endocrinologie - Hôpital de l'Archet I - Route Saint Antoine de Jinestière
Nice, France, 06202
Service de Cancérologie Médicale - HEGP - 20 rue Leblanc
Paris, France, 75015
Service d'Oncologie Médicale, Institut Claudius Regaud - 20-24 rue du Pont Saint Pierre
Toulouse, France, 31052
Service d'endocrinologie et Maladies Métaboliques, Groupe Hospitalier Rangueil-Larrey CHU Toulouse - avenue Prof Jean Poulhes
Toulouse, France, 31059
Service d'Endocrinologie - CHU de Nancy, Hôpital de Brabois - rue du Morvan
Vandoeuvre les Nancy, France, 54511
Sponsors and Collaborators
University Hospital, Bordeaux
Principal Investigator: Alain Ravaud, Pr. University Hospital, Bordeaux, France
Study Chair: Geneviève Chene, Pr. University Hospital, Bordeaux, France
  More Information

Responsible Party: University Hospital, Bordeaux Identifier: NCT00510640     History of Changes
Other Study ID Numbers: 9277-06
Study First Received: August 1, 2007
Last Updated: February 27, 2013

Keywords provided by University Hospital, Bordeaux:
thyroid carcinoma
RECIST guidelines

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors processed this record on April 25, 2017